Trastuzumab

Links to news articles on Trastuzumab .

ImmunoGen, Inc. Announces Extension of Technology Access Agreement ... -- 30 Mar 2006
...antibodies to deliver a potent cell-killing agent specifically to cancer cells. ... A fourth TAP compound, trastuzumab-DM1 in development by Genentech, now has an ... Genetic Engineering News,

EBCC Calls To Speed Access To Innovative Advances For All Breast ... -- Mar 28, 2006
Breast cancer doctors claim that the results of the four trials are sufficiently compelling to recommend adjuvant trastuzumab as a standard option after ... Medical News Today (press release),

Herceptin (trastuzumab) provisionally approved -- Mar 22, 2006
Herceptin or trastuzumab is a _cancer treatment which targets the HER2 protein ... and in addition to, completion of standard breast cancer treatments: surgery ... Scoop.co.nz (press release),

Herceptin Approved for Early Breast Cancer In NZ -- Mar 23, 2006
N Engl J Med 2005;353(16):1659-72. 2) Harries M, Smith I. The development and clinical use of Trastuzumab (Herceptin). Endocr Relat Cancer 9: 75-85, 2002. ... Scoop.co.nz (press release),

Taxotere®/Platinol®/Herceptin® Effective in Locally Advanced ... -- Mar 22, 2006
Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced Breast Cancer. ... Cancer Consultants (press release),

HOT OFF THE PRESS - 23 March 2006 -- Mar 22, 2006
Provisional consent limits the use of Herceptin (trastuzumab) to treat women with early breast cancer who test positive for the HER2 gene once they have had ... New Zealand Doctor Online,

Committee for Medicinal Products for Human Use Post-authorisation ... -- Mar 24, 2006
Taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and ... PharmaLive.com (press release),

Clodronate® in Early Breast Cancer May Reduce Risk of Developing ... -- Mar 21, 2006
...however, standard treatment for early breast cancer includes surgery, radiation therapy, chemotherapy, hormone therapy, and/or Herceptin® (trastuzumab). ... Cancer Consultants (press release),

Quick takes on health -- Mar 22, 2006
...with the early stage of a certain invasive breast cancer were less likely to have the cancer recur if they received Herceptin (trastuzumab) in combination with ... Rochester Democrat and Chronicle,

Separate Algorithm Spells Out Treatment for Hormonal Status of ... -- Mar 20, 2006
If the cancer is positive for both estrogen and progestin, the next ... nodal involvement are treated with hormonal therapy, chemotherapy and trastuzumab (Herceptin ... DG News

Micromet Study Provides New Insight into Dosing Requirements for ... -- Mar 2, 2006
Berheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? ... PharmaLive.com (press release),

In 2005 Important Advances Made in Breast Cancer Treatment and ... -- Mar 6, 2006
In two large clinical trials, trastuzumab (Herceptin), which has been available for women with advanced breast cancer, was found to help women with early-stage ... eMaxHealth.com,

Short course of Herceptin holds promise for breast cancer patients -- Mar 6, 2006
...generically as trastuzumab, is a monoclonal antibody, or a type of genetically engineered protein, used to treat an estimated 20 percent of breast cancer cases ... Centre Daily Times,

New Therapies Target Cancer -- Mar 7, 2006
In 1997, Herceptin (trastuzumab) became the first targeted therapy for breast cancer, specifically for HER2-positive metastatic breast cancer. ... Drug Discovery & Development (subscription),

Adjuvant therapy: Extra treatment to keep cancer from returning -- Mar 13, 2006
Women with breast cancer that makes too much of a protein called HER2 may choose a targeted therapy called trastuzumab (Herceptin) as adjuvant therapy. ... MayoClinic.com

Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ... -- Mar 6, 2006
...cancer. They also demonstrated the effectiveness of Herceptin (trastuzumab) for treatment of HER-2/neu positive breast cancer. The ... Cancer Consultants (press release),

Research and Markets: The FDA is Encouraging the Use of Biomarkers ... -- Mar 22, 2006
...diagnostics for molecularly targeted oncology drugs, including trastuzumab (Genentech's Herceptin ... and the advent of molecularly targeted cancer drugs is driving ... PharmaLive.com (press release),

Kosan Reports 2005 Fourth Quarter and Year End Results -- Mar 2, 2006
KOS-953 in combination with trastuzumab (Herceptin®) into a Phase II clinical trial in patients with HER2-positive metastatic breast cancer; -- Advancement of ... Yahoo! News (press release)

Antibodies are the first wave of IGF-1R antagonists for cancer ... -- Mar 6, 2006
...cloned in 1986, it was the success of targeted drugs such as trastuzumab and imatinib ... clinic may be: 1) the fear that blocking IGF-1R in cancer therapy would ... TransWorldNews (press release),

Exercise might help Parkinson’s patients -- Mar 7, 2006
Herceptin, known generically as trastuzumab, is a type of genetically engineered protein used to treat an estimated 20 percent of breast cancer cases in which ... The State,

Kosan Initiates Phase I Clinical Trial of Oral Hsp90 Inhibitor KOS ... -- 25 Jan 2006
...is being investigated by Kosan in a Phase II clinical trial in combination with trastuzumab (Herceptin®) in patients with Her2 positive breast cancer, as well ... Yahoo! News (press release)

Newest MD Anderson SPORE to Fund Breast Cancer Research -- Jan 20, 2006
...to use the protein, PTEN, to predict response and resistance to trastuzumab (Herceptin), a powerful drug used in the treatment of breast cancer patients whose ... PR Newswire (press release),

Immune Substances May Help Antibody-based Drugs Fight Cancer -- Jan 5, 2006
Trastuzumab is used to treat advanced breast cancer cases that over-produce the HER2 protein. The drug coats the tumor cells with ... Science Daily (press release)

Genentech's Shares Fall On Disappointing Avastin Sales -- Jan 11, 2006
Genentech's breast cancer drug, Herceptin (trastuzumab) posted fourth-quarter sales of $250.1 million, up 98 percent from fourth-quarter 2004 sales of $126 ... BioWorld Online (subscription),

Immune stimulants may help cancer patients, study shows -- Jan 9, 2006
The drug trastuzumab consists of an antibody that targets the protein HER2, which is present on cancer cells of many breast tumors. ... Pharmaceutical Business Review

New drug combo may boost cancer treatment -- Jan 5, 2006
...university said. Trastuzumab is used to treat advanced breast cancer cases that overproduce the HER2 protein. The investigators ... Science Daily (press release)

Immune-system boosters aid cancer drugs -- Jan 9, 2006
So says a new study from Ohio State University that found that the cancer drug Herceptin (trastuzumab) may be even more effective in fighting breast cancer ... United Press International

Genentech Announces Full Year and Fourth Quarter 2005 Results -- Jan 10, 2006
...success in clinical trial results and FDA filings for potential therapeutics to treat cancer, blindness and ... US sales of Herceptin(R) (Trastuzumab) in 2005 ... MSN Money

In 2005, Advances Made in Breast Cancer Treatment and Detection -- Dec 28, 2005
In two large clinical trials, trastuzumab (Herceptin), which has been available for women with advanced breast cancer, was found to help women with early-stage ... Newswise (press release)

Year saw strides against breast cancer -- Dec 30, 2005
Specifically, in two large clinical trials, trastuzumab (Herceptin), used to treat women with advanced breast cancer, was found to help women with early-stage ... United Press International

2005 A Good Year For Breast Cancer Treatments -- Dec 29, 2005
Researchers found that when trastuzumab (Herceptin) is used with chemotherapy treatment in treating early-stage HER-2 positive breast cancer, there was a 52 ... All Headline News

Pitt sees new role for cancer drug -- Dec 26, 2005
...one of its normal functions and trigger the death of cancer cells. ... Herceptin, or trastuzumab, consists of a specially developed antibody that attacks a protein ... Pittsburgh Post Gazette,

'My mother was sat beside me and I remember thinking 'If she's ... -- Jan 7, 2006
...m to the university's cancer work under Slamon's leadership between 1989 and 1997. As it entered the phase II trials, the drug finally had a name: trastuzumab. ... The Observer,

Genentech Announces Full Year and Fourth Quarter 2005 Results -- Jan 10, 2006
...success in clinical trial results and FDA filings for potential therapeutics to treat cancer, blindness and ... US sales of Herceptin® (Trastuzumab) in 2005 ... Yahoo! News (press release)

Herceptin plus chemotherapy improves disease-free survival in ... -- Jan 7, 2006
Herceptin ( Trastuzumab ) is effective in women with HER-2 positive breast cancer, about one in four diagnosed with the disease every year. ... Xagena.it,

Targeted cancer therapies: Another step forward -- Dec 22, 2005
...in the development and launch of Genentech/Roche's Herceptin (trastuzumab), which enrolled ... valuable and effective weapon in the fight against cancer, they will ... News-Medical.net,

Breast cancer therapeutics benefits from cytotoxic alternatives -- Dec 23, 2005
Cancer therapeutics cost to market will pose a challenge for smaller ... kinase inhibitor that is following in Genentech/Roche's Herceptin's (trastuzumab) footsteps ... In-PharmaTechnologist.com,

Targeted cancer therapies: another step forward -- 23 Dec 2005
...the development and launch of Genentech/Roche’s Herceptin (trastuzumab), which enrolled ... valuable and effective weapon in the fight against cancer, they will ... Pharmaceutical Business Review

Breast cancer therapeutics benefits from cytotoxic alternatives -- 23 Dec 2005
Cancer therapeutics cost to market will pose a challenge for smaller ... kinase inhibitor that is following in Genentech/Roche's Herceptin's (trastuzumab) footsteps ... In-PharmaTechnologist.com,

Targeted cancer therapies: Another step forward -- Dec 22, 2005
...in the development and launch of Genentech/Roche's Herceptin (trastuzumab), which enrolled ... valuable and effective weapon in the fight against cancer, they will ... News-Medical.net,

NCCN Includes Herceptin® in Guidelines as Therapy in HER2 ... -- Dec 21, 2005
Fortunately, the targeted agent Herceptin (trastuzumab) binds to HER2 receptors and prevents or reduces replication of cancer cells that overexpress HER2. ... Cancer Consultants (press release),

Cover Story: New hope for breast cancer -- Dec 19, 2005
...recommended for a year. Trastuzumab is still the best treatment for metastatic breast cancer patients (mbc) with over expression of HER2. ... New Straits Times,

Trastuzumab Used as First Line Therapy in Women Whose Cancer Has ... -- Dec 12, 2005
...[Presentation title: Effect of Trastuzumab Treatment as First-Line on Metastatic Breast Cancer: Final Results of the French HERMINE Cohort after 2-Year Follow ... DG News

Interim Analysis of Phase 3 Study Shows Taxotere (docetaxel)-Based ... -- Dec 16, 2005
SAN ANTONIO, TX -- December 16, 2005 -- The Breast Cancer International Research Group (BCIRG) and the sanofi-aventis Group today announced the results from ... DG News

Genentech Submits Supplemental Biologics License Application for ... -- Dec 19, 2005
Genentech is committed to changing the way cancer is treated ... development programs for Rituxan® (Rituximab), Herceptin® (Trastuzumab), Avastin® (bevacizumab ... Yahoo! News (press release)

Genentech Submits Supplemental Biologics License Application for ... -- Dec 19, 2005
Genentech is committed to changing the way cancer is treated by ... clinical development programs for Rituxan(R) (Rituximab), Herceptin(R) (Trastuzumab), Avastin(R ... PharmaLive.com (press release),

HER2-Positive Breast Cancer Doubles Risk of Brain Metastases ... -- Dec 12, 2005
...that the fact these women appear to have more brain metastases is because the trastuzumab protects them longer from the breast cancer progressing throughout ... DG News

Kosan Initiates Phase II Clinical Trial of KOS-953 in Combination ... -- Dec 8, 2005
Ib dose-escalating and Phase II clinical trials of KOS-953 in combination with trastuzumab are being conducted at Memorial Sloan- Kettering Cancer Center and ... PR Newswire (press release),

First Line Treatment with Herceptin Improves Outcomes in Early ... -- Dec 9, 2005
...and Cyclophosphamide Followed by Docetaxel and Trastuzumab with Docetaxel, Carboplatin and Trastuzumab in HER2 Positive Early Abreast Cancer Patients: BCIRG ... DG News

Addition of Herceptin® to Adjuvant Chemotherapy Improves Breast ... -- Dec 13, 2005
...from the HERA (Herceptin Adjuvant) Trial indicate that the addition of Herceptin (trastuzumab) to adjuvant chemotherapy for early breast cancer results in ... Cancer Consultants (press release),

Short Course of Herceptin® in Patients with Breast Cancer -- Dec 9, 2005
...al. Trastuzumab in Combination with Docetaxel or Vinorelbine as Adjuvant Treatment of Breast Cancer: the FinHer Trial. Proceedings ... Cancer Consultants (press release),

GlaxoSmithKline cancer drug threatens Herceptin market -- Dec 9, 2005
The first targeted therapy for breast cancer, Genentech's Herceptin (trastuzumab), approved in 1998 in the US, could soon face direct competition. ... Nature.com (subscription),

Breast cancer specialists to talk therapies, tests at SA meeting -- Dec 7, 2005
...today is to provide information on a drug known as Herceptin, or trastuzumab, in women carrying a specific genetic trait. The National Cancer Institute (NCI ... San Antonio Express (subscription),

Herceptin with Chemotherapy Improves Survival in Early Stage ... -- Dec 9, 2005
...cancer – an aggressive form of the disease found in about one-fourth of cases - can be reduced almost in half by taking the drug Herceptin (trastuzumab) ... SeniorJournal.com,

DELIVERING NEWS AND OPINION SINCE MAY 9, 2005 -- Dec 18, 2005
...governments, private insurance companies or employers) try to find ways to not pay for products like the breast cancer drug trastuzumab (Herceptin) or the ... Huffington Post,

Herceptin OK as upfront cancer drug -- Dec 9, 2005
Herceptin, known generically as trastuzumab, is targeted specifically at the breast cancer in which there is HER-2 over-expression. ... Monsters and Critics.com,

Interim Analysis on HERA Trial: Herceptin in Adjuvant Breast ... -- Dec 14, 2005
Trastuzumab (H: Herceptin) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 ... Cancer Consultants (press release),

Taxane-Based Breast Cancer Treatment Cost-Effective Compared to 5 ... -- Dec 13, 2005
HER2 positive patients would likely be treated with trastuzumab (Herceptin ... Effectiveness of Adjuvant Chemotherapy for Node Positive Breast Cancer: Modeling the ... DG News

Better Breast Cancer Treatment -- Dec 14, 2005
...a clinical trial to test a new therapy for breast cancer. Instead of chemo, doctors gave her a combination of two drugs -- Herceptin (trastuzumab) and Avastin ... drkoop.com

Non-Anthracycline Chemotherapy Regimen Plus Herceptin®: Effective ... -- Dec 13, 2005
Followed by Docetaxel and Trastuzumab (AC-TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in HER2 Positive Early Breast Cancer Patients: BCIRG 006 Study. ... Cancer Consultants (press release),

GlaxoSmithKline Initiates Trial Of Tykerb (Lapatinib) in Patients ... -- Dec 9, 2005
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. In press. 2005. ... PR Newswire (press release),

GSK Starts Tykerb Trial In Patients With ErbB2-Overexpressing ... -- Dec 11, 2005
1 HJ Stemmler et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. ... Medical News Today (press release),

(PRN) US Oncology Research Network Presenting Numerous Studies at ... -- Dec 11, 2005
Phase II trial of gemcitabine plus carboplatin (plus trastuzumab in HER2+ subjects) in metastatic breast cancer patients. The lead ... Houston Chronicle,

Herceptin Plus Chemotherapy Improves Disease-free Survival In ... -- Dec 8, 2005
Cancer (October 22, 2005) -- The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced ... Science Daily (press release)

(PRN) GlaxoSmithKline Initiates Trial Of Tykerb (Lapatinib) in ... -- Dec 9, 2005
...will begin enrolling patients with breast cancer who have progressive brain metastases following cranial radiotherapy and prior trastuzumab (Herceptin)-based ... Houston Chronicle,

C-myc Gene Influences Response to Herceptin® -- Dec 14, 2005
Trastuzumab Sensitivity of Breast Cancer with Co-Amplification of HER2 and cMYC Suggest Pro-Apoptotic Function of Dysregulated cMYC in Vivo. ... Cancer Consultants (press release),

Interim Analysis of Phase III Study Shows TAXOTERE(R)-Based ... -- Dec 8, 2005
HERCEPTIN(R) (trastuzumab) reduces the risk of recurrence without increasing cardiotoxicity in patients with early stage HER2-positive breast cancer SAN ANTONIO ... PR Newswire (press release),

Non-Anthracycline Regimens Plus Herceptin Effective with Less ... -- Dec 9, 2005
...containing regimens without the cardiotoxicity when used in addition with Herceptin (trastuzumab) for the adjuvant treatment of HER2-positive breast cancer. ... Cancer Consultants (press release),

SABCS: Herceptin-Anthracycline Cardiotoxicity Called Real and ... -- Dec 8, 2005
8 - Adjuvant breast cancer therapy with Herceptin (trastuzumab) in women with early HER2-positive tumors sharply improves disease-free survival, researchers ... MedPage Today,

Top Advances in Cancer Treatment for 2005 Chosen by Oncologists -- Dec 2, 2005
1. Trastuzumab (Herceptin) reduces recurrence of HER-2-positive early-stage breast cancer by half. Two large clinical trials showed ... SeniorJournal.com,

NCCN Announces Two New Breast Cancer Resources -- Dec 6, 2005
NCCN also expanded the adjuvant therapy regimens to include the addition of trastuzumab for patients with HER-2 positive breast cancer. ... Business Wire (press release),

Powerful Breast Cancer Drug Carries High Price -- Nov 29, 2005
Herceptin (trastuzumab) is a humanized monoclonal antibody drug that targets breast cancers ... Herceptin is licensed for use in advanced breast cancer, where it ... Forbes

Cancer Group Lists Top Treatment Advances for 2005 -- Dec 2, 2005
Herceptin (trastuzumab) combats breast cancer. Up to 30 percent of breast cancer patients have malignancies that overproduce the ... Forbes

Can healthcare systems afford Herceptin for early breast cancer ? -- Dec 6, 2005
A research into the cost of using the breast cancer drug Herceptin ( Trastuzumab ) warns that healthcare authorities and the organisations advising them should ... Xagena.it,

Can healthcare systems afford Herceptin for early breast cancer? -- Nov 29, 2005
Herceptin (trastuzumab) is a humanised monoclonal antibody that targets those breast ... currently licensed for use in advanced (metastatic) breast cancer where it ... EurekAlert (press release),

Cancer drug funding a challenge – PHARMAC -- Dec 5, 2005
...per patient. A new treatment for a type of brain cancer (temozolomide) or another for breast cancer (trastuzumab) are examples. ... Scoop.co.nz (press release),

New Drug Treatment Effective Against Some Breast Cancers -- Dec 1, 2005
...trastuzumab. Trastuzumab is an antibody that sticks to the HER2 receptor and prevents it from allowing the cancer cells to grow. It ... ABC News

Herceptin debate comes amid skepticism about all drugs -- Nov 24, 2005
Perhaps no other anti-cancer drug in recent memory has garnered more divergent opinions than trastuzumab, known by the brand name, Herceptin. ... Globe and Mail,

Early Use of Herceptin Cost-Effective if Survival Really Improves ... -- Dec 1, 2005
2005 (Agence de Presse Medicale for Reuters Health) - Roche's Herceptin (trastuzumab) is a ... turns out to be as powerful in early breast cancer as preliminary ... Cancerpage.com,

'It means the world to me' -- Nov 30, 2005
Herceptin, scientific name trastuzumab, uses the body's natural immune system to kill tumour and cancer cells. The drug tracks down ... ic CheshireOnline,

Clinical Trials 2005: A Year's Highlights -- Dec 5, 2005
One of those findings involves the drug Herceptin® (trastuzumab) and preliminary results from ... the drug was found to reduce the chances of cancer returning by ... CancerWise

Pork Loin Chops With Sweet and Hot Peppers -- 21 Nov 2005
...randomly assigned 3,387 women with HER2-positive breast cancer who had completed surgery and chemotherapy to receive trastuzumab (Herceptin) intravenously ... Charlotte Observer,

Gamma-linolenic acid inhibits action of Her-2/neu, responsible for ... -- Nov 20, 2005
...protein levels of the oncogene, but also caused a 30- to 40-fold increased response in breast cancer cells to the drug Herceptin ( Trastuzumab ), a monoclonal ... Xagena.it,

Hope or hype -- Nov 18, 2005
...the women taking Herceptin (Roche's brand name for the active ingredient, trastuzumab). ... and should be available to all women with Her2-positive breast cancer. ... Australian,

A New Loading Dose Schedule Gets Herceptin Patients To Steady ... -- Nov 18, 2005
...[Presentation title: A Novel Loading Regimen for Herceptin(R) (Trastuzumab) in Metastatic Breast Cancer Boosts Serum Levels in Early Cycles without ... DG News

Hillsboro woman puts life on line for other breast cancer patients -- Nov 13, 2005
Though Herceptin, which is the brand name for trastuzumab, a bioengineered monoclonal ... another scientist discovered an equivalent protein in breast cancer cells ... Bridgewater Courier News,

Drug provides targeted therapy -- Nov 14, 2005
HERCEPTIN Herceptin (generic name trastuzumab) is a monoclonal antibody; antibodies are part of the body's natural defense against cancer cells. ... New Brunswick Home News Tribune,

PM Sharon Urges Inclusion of Breast Cancer Drug in Health Basket -- Nov 6, 2005
...requested an additional NIS 100 million for his ministry’s budget in 2006 to add the breast cancer drug Herceptin, known generically as trastuzumab, to the ... Arutz Sheva,

Study Examines Anticancer Effect of Herbal Medicine in Cancer ... -- Nov 7, 2005
The researchers also found that treating the cancer cell lines with both GLA and trastuzumab led to a synergistic increase in apoptosis and reduced cell growth ... NPIcenter (press release),

Breast Cancer - Concurrent NCCTG and NSABP studies find ... -- Oct 21, 2005
...of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer. ... Medical News Today (press release),

Herceptin's benefits not proven, journal says -- Nov 11, 2005
...as a drug that is creating a paradigm shift in the breast-cancer treatment. ... rapidly adopted as the standard of care in the United States, trastuzumab was not ... Globe and Mail,

Headlines About Herceptin Show Equality Of Access To Costly Drugs ... -- Nov 5, 2005
The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of ... Medical News Today (press release),

Herceptin Treatment Lowers Recurrence Rate In Early Breast Cancer -- Oct 22, 2005
BRUSSELS - The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of ... Science Daily (press release)

Medical Community Recognise Significance of Herceptin Results in ... -- Oct 21, 2005
2. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9: 75-85, 2002. 3. Romond, E., Perez, E. et al. ... DG News

Landmark trial shows Herceptin cuts relapse rate -- Oct 21, 2005
However, trastuzumab and the two reports in this issue will completely alter our approach to the treatment of breast cancer," Hortobagyi concluded. Cancerfacts.com,

Primrose Oil Component Cuts Levels Of Cancer-causing Gene Her-2 ... -- Nov 4, 2005
...protein levels of the oncogene, but also caused a 30- to 40-fold increased response in breast cancer cells to the drug HerpetinTM (trastuzumab), a monoclonal ... Science Daily (press release)

Drug is effective against early-stage breast cancer -- Oct 20, 2005
Herceptin, known generically as trastuzumab, does not help everyone. For one thing, it is only for the estimated 20% of breast cancer cases in which tumors ... The Advocate,

HERA (HERceptin Adjuvant) Breast Cancer Trial Published in NEJM -- Oct 21, 2005
...trastuzumab) following standard chemotherapy significantly reduces the risk of disease recurrence for women with early-stage HER2-positive breast cancer by 46 ... RxPG NEWS,

Drug offers 'stunning' results in treating breast cancer -- Oct 23, 2005
Herceptin, known generically as trastuzumab, does not help everyone. It is used in only the estimated 20% of breast cancer cases in which tumors churn out too ... Jamaica Observer,

Primrose oil fatty acid blocks cancer-causing gene -- Nov 3, 2005
Her-2/neu with GLA there was a 30- to 40-fold increased response in the cells to the drug Herceptin (trastuzumab), a commonly used treatment for this cancer. ... Food Navigator,

Drug halves breast cancer relapse rate for some -- Oct 21, 2005
...breast cancer have such tumours, so 42,000 US women could benefit from the treatment, the report pblishers on Wednesday said. The drug is trastuzumab, sold ... NewKerala.com,

MassMutual Provides Life Insurance for Women with Breast Cancer -- Oct 25, 2005
...to be a leader in providing life insurance coverage for breast cancer survivors, updating ... detection and new treatments such as the use of trastuzumab (Herceptin ... PR Newswire (press release),

CANCER DRUG LISTING CALL -- Oct 25, 2005
PEAK cancer groups have called for rapid PBS listing of the cancer drug trastuzumab (Herceptin), after a finding that it almost halves breast cancer recurrence ... AustralianDoctor.com (subscription),

Balancing Benefits with Safety in Breast and Ovarian Cancer -- Oct 23, 2005
...of metastatic breast cancer. One particular area of interest and clinical research is the potential to safely combine CAELYX with trastuzumab in patients with ... PR Newswire UK (press release),

Herceptin Halves Risk of HER2-Positive Breast Cancer Recurrence -- Oct 22, 2005
Herceptin (trastuzumab) can halve the risk of breast cancer recurrence for women with early-stage HER2-positive tumors -- a relatively small group -- when it's ... Scoopt.org,

Two great strides toward curing cancer -- Nov 1, 2005
Researchers have developed a new drug, Herceptin (generic: trastuzumab), which holds great ... The head of breast-cancer therapeutics at NCI, Dr. Jo Anne Zujewski ... The Free Lance-Star,

New drug for breast cancer -- Oct 28, 2005
Pathologists have ways to determine whether the cancer biopsies they take have an ... began using Herceptin — the trade name for the drug trastuzumab, made by ... Danbury News Times,

Trastuzumab Efficacy ''Stunning'' in HER2-Positive Breast Cancer -- Oct 20, 2005
...up of 1 year, there were 127 events (recurrence of breast cancer, contralateral breast cancer, second malignant disease or death) in the trastuzumab group and ... Cancerpage.com,

Trastuzumab therapy effective for Breast cancer patients with Her ... -- Oct 20, 2005
...results showed that out of 1,679 control patients 261 patients developed recurrence breast cancer disease compared to 133 in the group receiving trastuzumab. ... MedIndia,

Multimedia News Release -- FDA Approves Tarceva(R) in Combination ... -- Nov 3, 2005
BioOncology Genentech is committed to changing the way cancer is treated ... development programs for Rituxan(R) (Rituximab), Herceptin(R) (Trastuzumab), Avastin(R ... PR Newswire (press release),

New monoclonal antibody therapies offer significant survival ... -- Nov 4, 2005
...of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after ... Medical News Today (press release),

Balancing Benefits with Safety in Breast and Ovarian Cancer -- Oct 24, 2005
...and clinical research is the potential to safely combine CAELYX with trastuzumab in patients with HER2- positive tumors. In advanced ovarian cancer, between 55 ... Biotech Intelligence (press release),

Drug halves breast cancer relapse rate for some -- Oct 19, 2005
They found a similar reduction in death or new cancer among women who got trastuzumab while receiving conventional chemotherapy. ... Reuters AlertNet,

Hype or Hope? -- Oct 24, 2005
Herceptin (trastuzumab) is an antibody targeted to a growth factor receptor called HER2 ... If the cancer doesn't express HER2, it will not respond to Herceptin. ... Corante

Multimedia News Release -- FDA Approves Tarceva(R) in Combination ... -- Nov 3, 2005
Genentech is committed to changing the way cancer is treated ... development programs for Rituxan® (Rituximab), Herceptin® (Trastuzumab), Avastin® (bevacizumab ... Yahoo! News (press release)

Early-stage breast cancer, Herceptin after adjuvant chemotherapy ... -- Oct 19, 2005
Herceptin ( Trastuzumab ), a recombinant monoclonal antibody against HER2, previously shown to prolong survival in advanced breast cancer, reduced the ... Xagena.it,

'Pockets' of women may miss breast cancer wonder drug: oncologist -- Oct 20, 2005
Thursday's issue of the New England Journal of Medicine confirms Herceptin (Trastuzumab) can cut the risk of cancer recurrence in half, and prolong life for ... CBC News,

Is it a bus? Is it a coach? No, it's a tram on wheels -- Nov 4, 2005
...to be reviewed using the rapid process will be docetaxel (Taxotere), paclitaxel (Taxol) and trastuzumab (Herceptin), all for breast cancer, rituximab (Mabthera ... Leeds Today,

Herceptin® Drastically Improves Cancer-Free Survival in Early ... -- Oct 20, 2005
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. ... Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. ... Cancer Consultants (press release),

Herceptin Halves Risk of HER2-Positive Breast Cancer Recurrence -- Oct 20, 2005
20 - Herceptin (trastuzumab) can halve the risk of breast cancer recurrence for women with early-stage HER2-positive tumors -- a relatively small group -- when ... MedPage Today,

Herceptin Proves a Wonder Drug for Breast Cancer -- Oct 19, 2005
Herceptin, also known as trastuzumab, works by halting the growth of those cancer cells. It is currently approved for the treatment ... Forbes

Court Aids Inmate; Bush Names Pro-Lifer to State -- Oct 22, 2005
The drug Herpecin (trastuzumab) has been found to dramatically improve outcomes among women with an aggressive form of breast cancer that accounts for between ... Women's eNews,

'That is revolutionary' -- Oct 20, 2005
Health. They found a similar reduction in death or new cancer among women who got trastuzumab with conventional chemotherapy. But ... OCRegister (subscription),

Breast cancer patients face 'terrible choice' -- Oct 19, 2005
The drug, also known as trastuzumab, is already subsidised for use in some advanced breast cancer, but extending that to treat early stage cancer has been ... Stuff.co.nz,

Drug "halves breast cancer relapse rate" -- Oct 19, 2005
About one in five women with breast cancer have such tumors. The drug is trastuzumab, sold under the brand name Herceptin by Genentech in the United States and ... Reuters

Study: drug cuts breast cancer relapse rate by half -- Oct 20, 2005
...; But the Herceptin treatment only works in women with early-stage HER-2 positive cancer. Herceptin, or trastuzumab, consists of antibodies that attack HER2 ... Xinhua,

Cancer drug 'simply stunning' -- Oct 20, 2005
Genentech and known by the generic name trastuzumab, has been used therapeutically on women in the advanced stages of HER2 breast cancer following chemotherapy ... News24,

Herceptin: The breast cancer wonder drug -- Oct 20, 2005
Herceptin is the brand name of the drug Trastuzumab. It is called a monoclonal antibody. This means that it is made in a lab to attack specific cancer cells. ... Daily Mail - UK,

Cancer drug gives new hope -- Oct 19, 2005
Herceptin, known generically as trastuzumab, is only for the estimated 20 percent of breast cancer cases in which tumors churn out too much of a protein known ... Pittsburgh Tribune-Review,

Drug proves to be highly effective against early breast cancer -- Oct 20, 2005
Dr. Jo Anne Zujewski, head of breast cancer therapeutics at the government’s National Cancer Institute. Herceptin, known generically as trastuzumab, does not ... The State,

Recurrence of Aggressive Breast Cancer Cut in Half by Herceptin -- Oct 20, 2005
...cancer – an aggressive form of the disease found in about one-fourth of cases - can be reduced almost in half by taking the drug Herceptin (trastuzumab) ... SeniorJournal.com,

Herceptin proves 'revolutionary' efficacy against breast cancer -- Oct 20, 2005
Herceptin or trastuzumab serves to halt their growth and is currently approved for treating HER 2 cancer that has spread beyond the breast. ... Earthtimes.org

Herceptin 'Revolutionary' for Breast Cancer -- Oct 20, 2005
...attending the annual meeting of the American Society of Clinical Oncology heard presentations about the breast cancer drug Herceptin (trastuzumab) that many ... ACS News Center,

Pivotal Herceptin Data in The New England Journal of Medicine ... -- Oct 19, 2005
Herceptin(R) (trastuzumab) plus chemotherapy. The analysis showed that the addition of Herceptin significantly reduced the risk of breast cancer recurrence by ... PR Newswire (press release),

Breast cancer drug halves tumour rate (Australian) -- Oct 19, 2005
In possibly the greatest breast cancer breakthrough in years, research has found that Herceptin (trastuzumab) halves the incidence of tumours recurring in ... AustralianDoctor.com (subscription),

Results of Herceptin studies called stunning -- Oct 20, 2005
...the drug, also known as trastuzumab, can receive it, according to the editorial written by Gabriel Hortobagyi, director of the Breast Cancer Research Program ... Globe and Mail,

Drug halves breast cancer relapse rate for some -- Oct 19, 2005
About one in five women with breast cancer have such tumors, so 42,000 US women could benefit from the treatment. The drug is trastuzumab, sold under the brand ... Reuters

Breast-cancer drug draws praise -- Oct 20, 2005
Herceptin, known generically as trastuzumab, does not help everyone. It is only for the 20 percent of breast-cancer cases in which tumors produce too much of a ... Winston-Salem Journal,

New drug changing treatment of breast cancers -- Oct 19, 2005
N. Hortobagyi, a medical oncologist at the MD Anderson Cancer Center in ... Herceptin, or trastuzumab, consists of antibodies that attack a protein called HER2 ... Pittsburgh Post Gazette,

Herceptin plus adjuvant chemotherapy improves outcomes among women ... -- Oct 19, 2005
...trials that compared adjuvant chemotherapy with or without concurrent Herceptin ( Trastuzumab ) in women with surgically removed HER2-positive breast cancer. ... Xagena.it,

Herceptin not for all -- Nov 4, 2005
Editorials and headlines called newly published findings on the breast cancer drug Herceptin (trastuzumab) "astounding" and "revolutionary," heralding a true ... myDNA.com,

Roche and Epitomics enter rabbit MAbs agreement -- Oct 19, 2005
...and development of monoclonal antibodies to treat cancer and other ... including Roche/Genentech's Avastin (bevacizumab) and Herceptin (trastuzumab) and Bristol ... in-PharmaTechnologist,

More information on Trastuzumab from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.